Correlation analysis of Xiakucao oral liquid combined with methimazole and rapid and stable recovery of thyroid function in patients with Graves' disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2024000684

Enrollment

Unknown

Registered

2024-11-11

Start date

2024-11-30

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

XKC+MMI Group:Xiakucao oral liquid combined with methimazole

MMI Group:methimazole

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) 18-75 years old; 2) Patients who were diagnosed with Graves' disease based on the "Primary Care Guidelines for Hyperthyroidism (2019) and treated in the Department of Endocrinology Jieyang People's Hospital from January 2019 to December 2023; 3) Patients who received treatment with methimazole (MMI) or MMI combined with Xiakucao oral liquid.

Exclusion criteria

Exclusion criteria: 1) Patients without laboratory test records; 2) Patients with age sex baseline thyroid function indicators and other important data missing.

Design outcomes

Primary

Measure	Time frame
The change of thyroid function index compared to baseline;	—

Countries

China

Contacts

Public ContactBichai Yuan

Jieyang People's Hospital

1215165756@qq.com13822072356

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026